Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

The epigenetics of diabetes, obesity, overweight and cardiovascular disease

Department of Biology, Faculty of science and health, Koya University Koya KOY45, Kurdistan Region-F.R. Iraq

The objectives of this review were once to understand the roles of the epigenetics mechanism in different types of diabetes, obesity, overweight, and cardiovascular disease. Epigenetics represents a phenomenon of change heritable phenotypic expression of genetic records taking place except changes in DNA sequence. Epigenetic modifications can have an impact on a whole of metabolic disease with the aid of specific alteration of candidate genes based totally on the change of the target genes. In this review, I summarized the new findings in DNA methylation, histone modifications in each type of diabetes (type 1 and type 2), obesity, overweight, and cardiovascular disease. The involvement of histone alterations and DNA methylation in the development of metabolic diseases is now widely accepted recently many novel genes have been demonstrated that has roles in diabetes pathway and it can be used for detection prediabetic; however Over the modern-day years, mass spectrometry-based proteomics techniques positioned and mapped one-of a kind range of histone modifications linking obesity and metabolic diseases. The main point of these changes is rapidly growing; however, their points and roles in obesity are no longer properly understood in obesity. Furthermore, epigenetic seen in cardiovascular treatment revealed a massive quantity of modifications affecting the improvement and development of cardiovascular disease. In addition, epigenetics are moreover involved in cardiovascular risk factors such as smoking. The aberrant epigenetic mechanisms that make a contribution to cardiovascular disease.
  Figure/Table
  Supplementary
  Article Metrics

References

1.Dimitri P, Corradini N, Rossi F, et al. (2005) The paradox of functional heterochromatin. Bioessays 27: 29–41.    

2.Muhonen P, Holthofer H (2008) Epigenetic and microRNA-mediated regulation in diabetes. Nephrol Dial Transplant 24: 1088–1096.    

3.Non AL, Thayer ZM (2019) Epigenetics and human variation, In: A companion to anthropological genetics, 21: 293–308.

4.Weksberg R, Butcher DT, Cytrynbaum C, et al. (2019) Epigenetics, In: Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics (Seventh Edition), 79–123.

5.American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus, In: Diabetes Care, 33: S62–S69.

6.Bullard KM, Cowie CC, Lessem SE, et al. (2018) Prevalence of diagnosed diabetes in adults by diabetes type-United States, 2016. Morbidity Mortality Wkly Rep 30: 359.

7.National Institutes of Health (2014) National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 188–210.

8.MacFarlane AJ, Strom A, Scott FW (2009) Epigenetics: Deciphering how environmental factors may modify autoimmune type 1 diabetes. Mamm Genome 1: 9–10.

9.Garvey WT (2019) Clinical Definition of Overweight and Obesity, In: Bariatric Endocrinology, 121–143.

10.Jensen MD, Ryan DH, Hu FB, et al. (2014) 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol 63: S102–S138.

11.Ling C, Rönn T (2019) Epigenetics in human obesity and type 2 diabetes. Cell Metab 29: 1028–1044.    

12.Roger VL, Go AS, Lloyd-Jones DM, et al. (2011) Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 123: e18–209.

13.Andreassi MG, Barale R, Iozzo P, et al. (2011) The association of micronucleus frequency with obesity, diabetes and cardiovascular disease. Mutagenesis 26: 77–83.    

14.Al-Hasani K, Mathiyalagan P, El-Osta A (2019) Epigenetics, cardiovascular disease, and cellular reprogramming. J Mol Cell Cardiol 128: 129–133.    

15.Smith CJ, Ryckman KK (2015) Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome. Diabetes Metab Syndr Obes 8: 295–302.

16.Xu L, Natarajan R, Chen Z (2019) Epigenetic risk profile of diabetic kidney disease in high-risk populations. Curr Diabetes Rep 19: 9.    

17.Keating ST, El‐Osta A (2013) Epigenetic changes in diabetes. Clin Genet 84: 1–10.    

18.Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 3: 245–254.

19.Pollin TI (2011) Epigenetics and diabetes risk: Not just for imprinting anymore? Diabetes 60: 1859–1860.    

20.Stankov K, Benc D, Draskovic D (2013) Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 132: 1112–1122.    

21.Bramswig NC, Kaestner KH (2012) Epigenetics and diabetes treatment: An unrealized promise? Trends Endocrinol Metabol 23: 286–291.    

22.Park JH, Stoffers DA, Nicholls RD, et al. (2008) Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest 118: 2316–2324.

23.Kulkarni RN, Jhala US, Winnay JN, et al. (2004) PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest 114: 828–836.    

24.Pinney SE, Simmons RA (2010) Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol Metabol 21: 223–229.    

25.Martínez JA, Milagro FI, Claycombe KJ, et al. (2014) Epigenetics in adipose tissue, obesity, weight loss, and diabetes. Adv Nutr 5: 71–81.    

26.Sommese L, Benincasa G, Schiano C, et al. (2019) Genetic and epigenetic-sensitive regulatory network in immune response: A putative link between HLA-G and diabetes. Expert Review Endocrinol Metabol 14: 233–241.    

27.Joyce B, Liu H, Wang L, et al. (2019) Abstract P073: A novel epigenetic link between gestational diabetes mellitus and macrosomia. Circulation 139: AP073.

28.Villeneuve LM, Reddy MA, Lanting LL, et al. (2008) Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Nat Acad Sci 105: 9047–9052.    

29.Miao F, Chen Z, Genuth S, et al. (2014) Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes 63: 1748–1762.    

30.Barros L, Eichwald T, Solano AF, et al. (2019) Epigenetic modifications induced by exercise: Drug-free intervention to improve cognitive deficits associated with obesity. Physiol Behav 204: 309–323.    

31.Ramos-Lopez O, Riezu-Boj JI, Milagro FI, et al. (2019) Associations between olfactory pathway gene methylation marks, obesity features and dietary intakes. Genes Nutr 14: 11.    

32.Xu L, Yeung MH, Yau MY, et al. (2019) Role of histone acetylation and methylation in obesity. Current Pharmacol Rep 5: 196–203.    

33.Romieu I, Dossus L, Barquera S, et al. (2017) Energy balance and obesity: What are the main drivers? Cancer Causes Control 28: 247–258.    

34.Austin GL, Ogden LG, Hill JO (2011) Trends in carbohydrate, fat, and protein intakes and association with energy intake in normal-weight, overweight, and obese individuals: 1971–2006. Am J Clin Nutr 93: 836–843.    

35.Ou XH, Zhu CC, Sun SC (2019) Effects of obesity and diabetes on the epigenetic modification of mammalian gametes. J Cellul Physiol 234: 7847–7855.    

36.Ayers D, Boughanem H, Macías-González M (2019) Epigenetic influences in the obesity/colorectal cancer axis: A novel theragnostic avenue. J Oncology: 7406078.

37.Duale N, Witczak O, Brunborg G, et al. (2019) Sperm Epigenome in Obesity. Handb Nutr Diet Epigenet: 727–744.

38.Castro R, Rivera I, Struys EA, et al. (2003) Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 49: 1292–1296.    

39.Stenvinkel P, Karimi M, Johansson S, et al. (2007) Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease? J Int Med 261: 488–499.    

40.Buro-Auriemma LJ, Salit J, Hackett NR, et al. (2013) Cigarette smoking induces small airway epithelial epigenetic changes with corresponding modulation of gene expression. Hum Mol Genet 22: 4726–4738.    

41.Ordovás JM, Smith CE (2010) Epigenetics and cardiovascular disease. Nat Rev Cardiol 7: 510.    

42.Webster AL, Yan MS, Marsden PA, et al. (2013) Epigenetics and cardiovascular disease. Can J Cardiol 29: 46–57.    

43.Shirodkar AV, Marsden PA (2011) Epigenetics in cardiovascular disease. Current Opin Cardiol 26: 209.    

44.Sun C, Burgner DP, Ponsonby AL, et al. (2013) Effects of early-life environment and epigenetics on cardiovascular disease risk in children: Highlighting the role of twin studies. Pediatr Res 73: 523.    

45.Huang RC, Lillycrop KA, Beilin LJ, et al. (2019) Epigenetic age acceleration in adolescence associates with BMI, inflammation and risk score for middle age cardiovascular disease. J Clin Endocrinol Metabol 104: 3012–3024.    

46.Elia L, Condorelli G (2019) The involvement of epigenetics in vascular disease development. Inter J Biochem Cell Biol 107: 27–31.    

47.Campos EI, Reinberg D (2009) Histones: Annotating chromatin. Annu Rev Gene 43: 559–599.    

48.Fedorova E, Zink D (2008) Nuclear architecture and gene regulation. BBA -Molecul Cell Res 1783: 2174–2184.

49.Kouzarides T (2007) Chromatin modifications and their function. Cell 128: 693–705.    

50.Duan L, Liu C, Hu J, et al. (2018) Epigenetic mechanisms in coronary artery disease: The current state and prospects. Trends Cardiovasc Med 28: 311–319.    

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline
Copyright © AIMS Press All Rights Reserved